Maxim Group Sticks to Its Buy Rating for scPharmaceuticals (SCPH)

In a report released yesterday, Naz Rahman from Maxim Group maintained a Buy rating on scPharmaceuticals (SCPHResearch Report), with a price target of $13.00. The company’s shares closed yesterday at $6.04.

Rahman covers the Healthcare sector, focusing on stocks such as Agile Therapeutics, 9 Meters Biopharma, and Clene. According to TipRanks, Rahman has an average return of -39.0% and a 17.95% success rate on recommended stocks.

Currently, the analyst consensus on scPharmaceuticals is a Strong Buy with an average price target of $14.25, which is a 135.93% upside from current levels. In a report released yesterday, SVB Securities also maintained a Buy rating on the stock with a $12.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

SCPH market cap is currently $165.7M and has a P/E ratio of -5.28.

Based on the recent corporate insider activity of 6 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SCPH in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

scPharmaceuticals, Inc.engages in the development of transformative pharmaceutical products for subcutaneous delivery. Its products include furosemide, used as parenteral diuretic in treating heart failure and ceftriaxone, used as parenteral antibiotic outside the hospital setting. The company was founded by Pieter Muntendam and Bertram Pitt in February 2013 and is headquartered in Burlington, MA.

Read More on SCPH:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More